These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36600109)

  • 41. Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia.
    Bergland AK; Dalen I; Larsen AI; Aarsland D; Soennesyn H
    J Alzheimers Dis; 2017; 56(2):575-584. PubMed ID: 28035932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.
    Leoutsakos JM; Forrester SN; Corcoran CD; Norton MC; Rabins PV; Steinberg MI; Tschanz JT; Lyketsos CG
    Int J Geriatr Psychiatry; 2015 Aug; 30(8):824-32. PubMed ID: 25363393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.
    Cedarbaum JM; Jaros M; Hernandez C; Coley N; Andrieu S; Grundman M; Vellas B;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S45-55. PubMed ID: 22658286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
    Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
    Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
    Rogers SL
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omega-3 fatty acids for the treatment of dementia.
    Burckhardt M; Herke M; Wustmann T; Watzke S; Langer G; Fink A
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009002. PubMed ID: 27063583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
    Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
    Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Free and Cued Selective Reminding Test Predicts Braak Stage.
    Grober E; Qi Q; Kuo L; Hassenstab J; Perrin RJ; Lipton RB
    J Alzheimers Dis; 2021; 80(1):175-183. PubMed ID: 33492287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort.
    Peakman G; Russell LL; Convery RS; Nicholas JM; Van Swieten JC; Jiskoot LC; Moreno F; Sanchez-Valle R; Laforce R; Graff C; Masellis M; Tartaglia MC; Rowe JB; Borroni B; Finger E; Synofzik M; Galimberti D; Vandenberghe R; de Mendonça A; Butler CR; Gerhard A; Ducharme S; Le Ber I; Tagliavini F; Santana I; Pasquier F; Levin J; Danek A; Otto M; Sorbi S; Rohrer JD;
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):158-168. PubMed ID: 34353857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional assessment staging (FAST) in Korean patients with Alzheimer's disease.
    Na HR; Kim SY; Chang YH; Park MH; Cho ST; Han IW; Kim TY; Hwang SA
    J Alzheimers Dis; 2010; 22(1):151-8. PubMed ID: 20847407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.
    Teipel SJ; Temp AGM; Lutz MW
    Alzheimers Dement (N Y); 2024; 10(1):e12454. PubMed ID: 38389855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
    Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
    J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.
    Scheltens NME; Tijms BM; Heymans MW; Rabinovici GD; Cohn-Sheehy BI; Miller BL; Kramer JH; Wolfsgruber S; Wagner M; Kornhuber J; Peters O; Scheltens P; van der Flier WM;
    J Alzheimers Dis; 2018; 65(3):1029-1039. PubMed ID: 30103316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of Muscle Profile in Alzheimer's Disease: A 3-Year Longitudinal Study.
    Moon Y; Moon WJ; Kim JO; Kwon KJ; Han SH
    Eur Neurol; 2019; 81(5-6):209-215. PubMed ID: 31655799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.